mAb Update: Prophylaxis Indication

Andrew B. Watkins, PharmD, BCIDP
Pharmacy Coordinator, Nebraska ASAP

ICAP
Infection Control Assessment and Promotion Program

Casirivimab-Imdevimab Prophylaxis Indication

As of 7/30/2021, casirivimab-imdevimab (no other mAb) has been authorized for use as **post-exposure prophylaxis** in:

- Adult and pediatric individuals (12 years of age and older weighing at least 40 kg) for post-exposure prophylaxis of COVID-19 in individuals who are at high risk for progression to severe COVID-19, including hospitalization or death, **and are**:
- Not fully vaccinated **or** who are not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination (for example, individuals with immunocompromising conditions including those taking immunosuppressive medications) **AND**
  - Have been exposed to an individual infected with SARS-CoV-2 consistent with close contact criteria per CDC **or**
  - Who are at high risk of exposure to an individual infected with SARS-CoV-2 because of occurrence of COVID-19 infection in other individuals in the same institutional setting (for example, nursing homes or prisons)

Asymptomatic positives can also receive prophylaxis

https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-regen-cov-monoclonal-antibody-therapy-post-exposure-prophylaxis-prevention-covid-19

Casirivimab-Imdevimab Prophylaxis Indication

Post-exposure prophylaxis dose is same as treatment dose (600 mg casirivimab + 600 mg imdevimab)

- For individuals with continued risk of exposure >4 weeks, a repeat dose of 300 mg casirivimab + 300 mg imdevimab can be given once every 4 weeks

Can be administered as IV infusion or subcutaneous injection for post-exposure prophylaxis

Updated provider fact sheet: https://www.fda.gov/media/145611/download

If you have patient(s) who you consider eligible for and interested in mAb for prophylaxis, or for any questions, please email Anwatkins@nebraskamed.com or call 662-820-1509.